IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells

Multiple myeloma is an incurable disease for the majority of patients, therefore requiring new biological targeted therapies. In primary myeloma cells, IMP dehydrogenase (IMPDH) was shown to be consistently overexpressed. We therefore tested the IMPDH inhibitor mycophenolate mofetil (MMF) currently available as a clinical therapeutic agent for its antimyeloma activity in vitro. MMF depleted intracellular guanosine 5′-triphosphate (GTP) levels in myeloma cells. We showed apoptosis induction in myeloma cell lines and primary myeloma cells between 1 and 5 μmol/L MMF. MMF was also cytotoxic at this concentration in dexamethasone-resistant and Mcl-1-overexpressed myeloma cell lines shown by the tetrazolium salt XTT assay along with cell survival measured by a modified flow cytometric assay. Apoptosis was not inhibited by the presence of an antioxidant, suggesting that MMF-induced apoptosis is less likely to be associated with reactive oxygen species. However, apoptosis was abrogated by exogenously added guanosine, which activates an alternative pathway for GTP formation, implicating that this effect is directly mediated by IMPDH inhibition. MMF-induced G1-S phase cell cycle arrest and its apoptosis induction mechanism were associated with a caspase-dependent pathway as shown by alteration of mitochondrial membrane potential and cytochrome c release followed by activation of the caspases. MMF-induced apoptosis was also inhibited by a pan-caspase inhibitor Z-VAD-fmk. MMF-treated myeloma cells showed an up-regulation of Bak, which most likely together with Bax resulted in the release of cytochrome c. In summary, MMF attenuates G1-S phase cell cycle progression and activates the pathway of mitochondrial dysfunction, leading to cytochrome c release followed by activation of caspases. [Mol Cancer Ther 2006;5(2):457–66]

[1]  Shaji K. Kumar,et al.  Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway , 2005, Oncogene.

[2]  J. Shaughnessy,et al.  Phase I Clinical Trial of the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolate Mofetil (Cellcept) in Advanced Multiple Myeloma Patients , 2004, Clinical Cancer Research.

[3]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[4]  S. Grant,et al.  Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors , 2004, Clinical Cancer Research.

[5]  D. Chauhan,et al.  Apoptosis in multiple myeloma: Therapeutic implications , 2001, Apoptosis.

[6]  William A. Lee,et al.  Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization , 1990, Pharmaceutical Research.

[7]  B. Mitchell,et al.  Targeted Disruption of the Inosine 5′-Monophosphate Dehydrogenase Type I Gene in Mice , 2003, Molecular and Cellular Biology.

[8]  S. Korsmeyer,et al.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. , 2003, Cancer research.

[9]  Bin Zhang,et al.  Proliferation of IL‐6‐independent multiple myeloma does not require the activity of extracellular signal‐regulated kinases (ERK1/2) , 2002, Journal of cellular physiology.

[10]  N. Munshi,et al.  Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. , 2002, Molecular cancer therapeutics.

[11]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[12]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[13]  John Calvin Reed,et al.  Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells* , 2001, The Journal of Biological Chemistry.

[14]  R. K Srivastava,et al.  Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.

[15]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[16]  J C Reed,et al.  Mechanisms of mitochondrial membrane permeabilization , 2000, Cell Death and Differentiation.

[17]  H. Iwasaki,et al.  Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil. , 2000, Leukemia research.

[18]  A. Allison,et al.  Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.

[19]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[20]  J. Avruch,et al.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR , 2000, Current Biology.

[21]  G. Hajnóczky,et al.  Apoptosis driven by IP3‐linked mitochondrial calcium signals , 1999, The EMBO journal.

[22]  G. Kroemer,et al.  Mitochondrial control of apoptosis: an overview. , 1999, Biochemical Society symposium.

[23]  J. Caulfield,et al.  Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. , 1999, Transplantation.

[24]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[25]  R. Bataille,et al.  Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy , 1999, Leukemia.

[26]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[27]  M. Urashima,et al.  Anti-estrogens induce apoptosis of multiple myeloma cells. , 1998, Blood.

[28]  P. Schollmeyer,et al.  Pharmacokinetics of mycophenolic acid after renal transplantation. , 1998, Transplantation proceedings.

[29]  L. Shaw,et al.  Scientific principles for mycophenolic acid therapeutic drug monitoring. , 1998, Transplantation proceedings.

[30]  M. Urashima,et al.  Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism , 1997, Oncogene.

[31]  T. Yamauchi,et al.  A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. , 1996, Cancer research.

[32]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[33]  Z. Oltvai,et al.  Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[35]  A. Lichtenstein,et al.  Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.

[36]  Matthew J. Brauer,et al.  Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak , 1995, Nature.

[37]  G. Evan,et al.  Induction of apoptosis by the Bcl-2 homologue Bak , 1995, Nature.

[38]  N. Ahmed,et al.  Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells. , 1995, Leukemia research.

[39]  H. Sollinger.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995, Transplantation.

[40]  B. Barlogie,et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.

[41]  N. Roehm,et al.  An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. , 1991, Journal of immunological methods.

[42]  F. Collart,et al.  Expression of IMP dehydrogenase in differentiating HL-60 cells. , 1990, Blood.

[43]  G. Tricot,et al.  Tiazofurin: biological effects and clinical uses. , 1990, International journal of cell cloning.

[44]  J. Ordonez,et al.  Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. , 1989, Cancer research.

[45]  N. Heerema,et al.  Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. , 1989, Cancer research.

[46]  A. Sartorelli,et al.  Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase. , 1986, Cancer research.

[47]  K. Paull,et al.  2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. , 1982, Journal of medicinal chemistry.

[48]  R. Jackson,et al.  IMP dehydrogenase, an enzyme linked with proliferation and malignancy , 1975, Nature.